Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Trastuzumab Plus Pyrotinib for Residual Invasive HER2-positive Breast Cancer After Neoadjuvant Chemotherapy Plus Anti-HER2 Target Therapy

NCT04254263 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT04254263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04254263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Trastuzumab Plus Pyrotinib for Residual Invasive HER2-positive Breast Cancer After Neoadjuvant Chemotherapy Plus Anti-HER2 Target Therapy
Lead sponsor
RenJi Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
December 16, 2019
Completion date
August 31, 2028
Enrollment
316 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced breast cancer